TOP TEN perturbations for 1552388_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552388_at
Selected probe(set): 1552388_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552388_at (1552388_at) across 6672 perturbations tested by GENEVESTIGATOR:

rheumatoid arthritis study 65 (adalimumab; poor resp.) / rheumatoid arthritis study 65 (adalimumab; good resp.)

Relative Expression (log2-ratio):-2.5724802
Number of Samples:3 / 3
Experimental rheumatoid arthritis study 65 (adalimumab; poor resp.)
Synovial tissue biopsy samples from patients with active rheumatoid arthritis (RA) obtained 12 weeks after treatment with adalimumab. Subjects had poor clinical response to the therapy which was assessed by DAS28-CRP values and according to the EULAR criteria. Adalimumab therapy was initiated at a dosage of 40 mg subcutaneously every other week. All patients were resistant to the conventional therapy. Biopsy samples were collected from affected knee by needle arthroscopy. Patients met the American College of Rheumatology criteria (1987) for the diagnosis of RA and had erosive changes imaged on conventional x-rays of the hands and/or feet. All of them had a swollen knee at inclusion. During the study using of injection steroids were forbidden. ATC code:
Control rheumatoid arthritis study 65 (adalimumab; good resp.)
Synovial tissue biopsy samples from patients with active rheumatoid arthritis (RA) obtained 12 weeks after treatment with adalimumab. Subjects had good clinical response to the therapy which was assessed by DAS28-CRP values and according to the EULAR criteria. Adalimumab therapy was initiated at a dosage of 40 mg subcutaneously every other week. All patients were resistant to the conventional therapy. Biopsy samples were collected from affected knee by needle arthroscopy. Patients met the American College of Rheumatology criteria (1987) for the diagnosis of RA and had erosive changes imaged on conventional x-rays of the hands and/or feet. All of them had a swollen knee at inclusion. During the study using of injection steroids were forbidden. ATC code:

ovarian tumor study 14 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-2.2283382
Number of Samples:4 / 4
Experimental ovarian tumor study 14
Human pooled cancer samples from the ovary of patients with moderate and poorly differentiated serous carcinoma of the ovary.
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)

Relative Expression (log2-ratio):2.1849623
Number of Samples:6 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted).

rheumatoid arthritis study 65 (adalimumab; poor resp.) / rheumatoid arthritis study 65 (adalimumab; moderate resp.)

Relative Expression (log2-ratio):-2.1752682
Number of Samples:3 / 5
Experimental rheumatoid arthritis study 65 (adalimumab; poor resp.)
Synovial tissue biopsy samples from patients with active rheumatoid arthritis (RA) obtained 12 weeks after treatment with adalimumab. Subjects had poor clinical response to the therapy which was assessed by DAS28-CRP values and according to the EULAR criteria. Adalimumab therapy was initiated at a dosage of 40 mg subcutaneously every other week. All patients were resistant to the conventional therapy. Biopsy samples were collected from affected knee by needle arthroscopy. Patients met the American College of Rheumatology criteria (1987) for the diagnosis of RA and had erosive changes imaged on conventional x-rays of the hands and/or feet. All of them had a swollen knee at inclusion. During the study using of injection steroids were forbidden. ATC code:
Control rheumatoid arthritis study 65 (adalimumab; moderate resp.)
Synovial tissue biopsy samples from patients with active rheumatoid arthritis (RA) obtained 12 weeks after treatment with adalimumab. Subjects had moderate clinical response to the therapy which was assessed by DAS28-CRP values and according to the EULAR criteria. Adalimumab therapy was initiated at a dosage of 40 mg subcutaneously every other week. All patients were resistant to the conventional therapy. Biopsy samples were collected from affected knee by needle arthroscopy. Patients met the American College of Rheumatology criteria (1987) for the diagnosis of RA and had erosive changes imaged on conventional x-rays of the hands and/or feet. All of them had a swollen knee at inclusion. During the study using of injection steroids were forbidden. ATC code:

rheumatoid arthritis study 64 (RTX; mPRED; 12wk; poor resp.) / rheumatoid arthritis study 64 (RTX; mPRED; 12wk; moderate resp.)

Relative Expression (log2-ratio):-2.1721916
Number of Samples:3 / 6
Experimental rheumatoid arthritis study 64 (RTX; mPRED; 12wk; poor resp.)
Synovium tissue samples from patients with active rheumatoid arthritis (RA) collected 12 weeks after treatment with rituximab (RTX) and methylprednisolone (mPRED). These patients were evaluated as poor responders (non-responders) to the treatment according to the European League Against Rheumatism (EULAR) response criteria. RTX was administered intravenously at a dose of 1,000 mg at baseline and at week 2, together with 125 mg intravenously mPRED. The patients fulfilled the American College of Rheumatology 1987 revised classification criteria for RA. All had erosive changes imaged on conventional radiographs of the hands and/or feet. Each of them had a swollen knee at inclusion. Synovial biopsies were obtained by needle arthroscopy of an affected knee. For RNA isolation 4 – 8 synovial biopsy samples were used. rituximab ATC code: methylprednisolone ATC code:, ,
Control rheumatoid arthritis study 64 (RTX; mPRED; 12wk; moderate resp.)
Synovium tissue samples from patients with active rheumatoid arthritis (RA) collected 12 weeks after treatment with rituximab (RTX) and methylprednisolone (mPRED). These patients were evaluated as moderate responders to the treatment according to the European League Against Rheumatism (EULAR) response. RTX was administered intravenously at a dose of 1,000 mg at baseline and at week 2, together with 125 mg intravenously mPRED. The patients fulfilled the American College of Rheumatology 1987 revised classification criteria for RA. All had erosive changes imaged on conventional radiographs of the hands and/or feet. Each of them had a swollen knee at inclusion. Synovial biopsies were obtained by needle arthroscopy of an affected knee. For RNA isolation 4 – 8 synovial biopsy samples were used. rituximab ATC code: methylprednisolone ATC code:, ,

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary)

Relative Expression (log2-ratio):2.1097565
Number of Samples:6 / 3
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted).

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)

Relative Expression (log2-ratio):2.0242243
Number of Samples:6 / 5
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, dedifferentiated liposarcoma of the soft tissue (subcutaneously implanted).

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)

Relative Expression (log2-ratio):1.9918852
Number of Samples:6 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted).

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)

Relative Expression (log2-ratio):1.9619141
Number of Samples:6 / 5
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted).

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)

Relative Expression (log2-ratio):-1.8760986
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).